title: Administration of optimum sustained-insulin release PLGA microcapsules to spontaneous diabetes-prone BB/Wor//Tky rats.
abstract: To show the possibility of sustained-release insulin formulation composed of PLGA, the optimum one was administered to BioBreeding rat, a model of spontaneous type I diabetes mellitus (IDDM). Every 2 weeks subcutaneous administration made their blood glucose level depend on the insulin release and food intake. However, all of them kept alive with little change or rather a little gain in body weight. Furthermore, some of pregnant rats with intermittent treatment bore fetuses, although additional insulin therapy seemed necessary. Therefore, the formulation could become a new tool as a provider of basal insulin for IDDM patients.
authors.affiliation: Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan. m2take@marianna-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Takenaga
authors.forename: Y
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Ogawa
authors.forename: A
authors.initials: A
authors.lastname: Kitagawa
authors.forename: S
authors.initials: S
authors.lastname: Kawai
authors.forename: Y
authors.initials: Y
authors.lastname: Mizushima
authors.forename: R
authors.initials: R
authors.lastname: Igarashi
authors.forename: M
authors.initials: M
authors.lastname: Namae
authors.forename: K
authors.initials: K
authors.lastname: Komeda
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight / Q000187:drug effects; D002214:Capsules; D003692:Delayed-Action Preparations / Q000008:administration & dosage*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004337:Drug Carriers; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry; D019344:Lactic Acid / Q000737:chemistry*; D008297:Male; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry*; D011247:Pregnancy; D051381:Rats; D011913:Rats, Inbred BB; D017208:Rats, Wistar; D012737:Sex Factors; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D002214:Capsules; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D007004:Hypoglycemic Agents; D007328:Insulin; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid